TP53 and cancer: Niclosamide significantly sensitized p53 mutant ovarian (OVCAR-8, TYK-nu) and breast (SKBR3, MDA-MB-231, T47D) cancer cells to niclosamide (Fig. 2e, f), as revealed by a significantly lowered mean IC50 value for the mutant p53 cancer lines compared to the wild-type p53 lines (Fig. 2e).